An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs M 4344 (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
- 01 Jun 2017 Planned End Date changed from 1 Mar 2017 to 1 Nov 2018.
- 01 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Nov 2018.
- 09 Feb 2017 Planned End Date changed from 1 Jan 2018 to 1 Mar 2017.